Jan. 15 at 4:06 PM
$ACRV "The
$69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush"
Acrivon Therapeutics, Inc. (NASDAQ:
$ACRV) announced positive data from its ACR-368 Phase 2b trial in endometrial cancer, showing a 39% overall response rate in OncoSignature-positive patients with a 67% confirmed response rate in BM-positive patients with serous subtype. The company has expanded the trial into the European Union.
"We are particularly excited by the observation from our ongoing ACR-368 Phase 2 trial that subjects with serous endometrial cancer with up to two prior lines of therapy are showing over 50% confirmed response rate," said Peter Blume-Jensen, M.D., Ph.D., CEO, President and co-founder of Acrivon Therapeutics.
*Acrivon submitted a Phase 3 confirmatory protocol to the FDA for ACR-368
Oncolytics Biotech Inc. (NASDAQ:
$ONCY), BriaCell Corp. (NASDAQ:
$BCTX) (TSX:http://BCT.TO), Perspective Therapeutics (NYSE-A:
$CATX), and #Greenwich (NASDAQ:
$GLSI).
